- Home
- NVR vs WAT Comparison
NVR vs WAT Comparison
Compare NVR & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVR
- WAT
- Stock Information
- Founded
- NVR 1980
- WAT 1958
- Country
- NVR United States
- WAT United States
- Employees
- NVR N/A
- WAT N/A
- Industry
- NVR Homebuilding
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- NVR Consumer Discretionary
- WAT Industrials
- Exchange
- NVR Nasdaq
- WAT Nasdaq
- Market Cap
- NVR 22.4B
- WAT 17.8B
- IPO Year
- NVR N/A
- WAT 1995
- Fundamental
- Price
- NVR $8,190.66
- WAT $306.63
- Analyst Decision
- NVR Buy
- WAT Hold
- Analyst Count
- NVR 4
- WAT 14
- Target Price
- NVR $8,783.33
- WAT $374.07
- AVG Volume (30 Days)
- NVR 16.9K
- WAT 603.2K
- Earning Date
- NVR 10-21-2025
- WAT 10-31-2025
- Dividend Yield
- NVR N/A
- WAT N/A
- EPS Growth
- NVR N/A
- WAT 10.77
- EPS
- NVR 474.94
- WAT 11.09
- Revenue
- NVR $10,717,672,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- NVR N/A
- WAT $7.15
- Revenue Next Year
- NVR N/A
- WAT $6.34
- P/E Ratio
- NVR $17.23
- WAT $27.68
- Revenue Growth
- NVR 5.86
- WAT 5.89
- 52 Week Low
- NVR $6,562.85
- WAT $275.05
- 52 Week High
- NVR $9,964.77
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- NVR 50.54
- WAT 55.20
- Support Level
- NVR $8,217.49
- WAT $294.96
- Resistance Level
- NVR $8,429.99
- WAT $311.44
- Average True Range (ATR)
- NVR 186.80
- WAT 9.19
- MACD
- NVR -37.31
- WAT 1.02
- Stochastic Oscillator
- NVR 27.61
- WAT 80.99
About NVR NVR Inc.
NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the Mid-Atlantic, North East, Mid-East, and South East.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.